Characterisation of an influenza B variant selected with the neuraminidase inhibitor zanamivir
Cheam, Ai Lee, Barr, Ian, Mosse, Jennifer, Hampson, Alan, and Hurt, Aeron (2004) Characterisation of an influenza B variant selected with the neuraminidase inhibitor zanamivir. International Congress Series, 1263 . pp. 122-125.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1016/j.ics.2004.02....
In order to study the generation of influenza viruses resistant to neuraminidase (NA) inhibitors, a recent influenza type B virus was passaged in vitro in the presence of increasing concentrations of zanamivir (0.1–1000 μM). A total of nine passages were carried out and, following the fifth passage at 10 μM, a mutation in the neuraminidase gene at Glu 119 Asp (N2 numbering) which is part of the enzyme active site was observed. Following another three passages in 100 μM of zanamivir, a further mutation in the HA1 domain of the haemagglutinin (HA) (Gln 218 Lys) (H3 numbering) was found. When compared with the wild-type virus, the passage levels containing the NA mutation exhibited a 32,000-fold reduction in sensitivity to zanamivir and a 105-fold reduction to oseltamivir carboxylate using a fluorescence-based neuraminidase inhibition assay. As a result of the mutation in the HA1 region of the haemagglutinin, a minor reduction in receptor binding strength in vitro was observed compared with the wild-type.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||neuraminidase inhibitors; zanamivir; oseltamivir; in vitro|
|FoR Codes:||06 BIOLOGICAL SCIENCES > 0605 Microbiology > 060506 Virology @ 100%|
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920109 Infectious Diseases @ 100%|
|Deposited On:||17 Apr 2010 15:11|
|Last Modified:||12 Feb 2011 22:52|
Last 12 Months: 0
Repository Staff Only: item control page